Title:
BEZAFIBRATE PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF IN RHEUMATOID ARTHRITIS
Document Type and Number:
WIPO Patent Application WO/2017/220041
Kind Code:
A3
Abstract:
Disclosed are a bezafibrate pharmaceutical composition and an application thereof in rheumatoid arthritis. The bezafibrate pharmaceutical composition contains bezafibrate and a natural product compound (I) separated from dried clove buds and having a novel structure. The joint action of the bezafibrate and the compound (I) causes synovial cell stagnation in the G1 phase of the cell cycle, thereby inhibiting synovial cell proliferation, and treating rheumatoid arthritis. The treatment effect is better than the effect of the single action of the bezafibrate or the compound (I). The bezafibrate and compound (I) composition may be developed into a drug treating rheumatoid arthritis, and has prominent substantive features and represents notable progress with respect to the prior art.
Inventors:
CUI KUNFENG (CN)
Application Number:
PCT/CN2017/097766
Publication Date:
February 15, 2018
Filing Date:
August 17, 2017
Export Citation:
Assignee:
ZHAO JIYONG (CN)
International Classes:
A61K31/365; A61K31/192; A61P19/02; A61P29/00; C07D307/93
Foreign References:
| CN106109461A | 2016-11-16 | |||
| CN104161750A | 2014-11-26 |
Download PDF: